Purchase Order 36C25021P2207
Award Date 9/23/21
Potential Completion Date 9/27/21
Potential Value $95K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92130, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed price purchase order awarded to Travere Therapeutics, Inc., a biopharmaceutical company specializing in rare disease therapies, by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) for the supply of the pharmaceutical product CHENODAL 250 MG 6 DOSES. The contract, which has a potential value of $236,500.00, has a completion date of December 30, 2022. Travere Therapeutics holds a General Services Administration (GSA) Schedule contract for...
- This is a firm fixed price purchase order awarded by the Department of Veterans Affairs Veterans Health Administration to Travere Therapeutics, Inc., a biopharmaceutical company, for the supply of CHENODAL 250MG. The potential value of the award is $236,500.00, with a completion date of September 30, 2022. The contract is not associated with any set-aside program. Travere Therapeutics, Inc. is a for-profit organization and manufacturer of goods that has received numerous federal contract...
- This is a firm fixed-price delivery order award to Travere Therapeutics, Inc., a biopharmaceutical company, by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 21. The contract is for the supply of Travere's specialty pharmaceutical product Filspari 400mg, which is used to treat rare diseases affecting kidney and liver function. The award has a ceiling value of $7,354.26 and a period of performance through September 30, 2024. Travere Therapeutics holds a Federal Supply...
- This federal contract award is a delivery order issued by the Department of Veterans Affairs (VA) to Travere Therapeutics, Inc., a biopharmaceutical company specializing in rare disease therapies. The contract, valued at $10,888.08, is for the supply of the pharmaceutical drug FILSPARI 200 MG. The contract was awarded through the VA's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), and is a firm fixed-price delivery order with a completion date of June 11, 2025. Travere...
- This federal contract award was issued by the Department of Veterans Affairs (VA) Veterans Health Administration to Travere Therapeutics, Inc. for the delivery of the pharmaceutical product Chenodal. The firm fixed price purchase order, valued at $189,200.00, has a completion date of September 30, 2022. Travere Therapeutics is a biopharmaceutical company that specializes in rare disease therapies and has received numerous federal contract awards from the VA and other agencies to supply...
- This federal contract award was made by the Department of Veterans Affairs (VA) to Travere Therapeutics, Inc., a biopharmaceutical company specializing in rare disease therapies. The $212,584.00 firm fixed-price purchase order is for the delivery of pharmaceutical drugs, with a period of performance ending on September 30, 2025. Travere Therapeutics holds a Federal Supply Schedule (FSS) contract with the VA as well as two Blanket Purchase Agreements (BPAs) specifically covering the procurement...
- This is a federal contract award issued by the Veterans Integrated Service Network 20 (VISN 20) of the U.S. Department of Veterans Affairs (VA) to Travere Therapeutics, Inc. The contract is for the delivery of the pharmaceutical product Filspari, with a ceiling value of $11,280.64 and a completion date of December 18, 2024. The contract is a Delivery Order under Travere's Federal Supply Schedule (FSS) contract with the VA for Pharmaceuticals and Drugs (FSS-61-IB). Additionally, Travere holds two...
- The Department of Veterans Affairs (VA) Veterans Health Administration awarded a firm fixed price delivery order to Travere Therapeutics, Inc., a biopharmaceutical company, to provide the pharmaceutical drug FILSPARI 200 MG. The contract, valued at $11,280.64, was issued under Travere's Pharmaceuticals and Drugs GSA Schedule contract and will be used to supply VA medical facilities in support of healthcare services for veterans. The contract does not have a set-aside designation. Travere...
- Travere Therapeutics, Inc. was awarded a $11,280.58 firm fixed price delivery order from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21. The delivery order was issued under Travere's Pharmaceuticals and Drugs General Services Administration Federal Supply Schedule contract to supply FILSPARI to VA medical facilities located in San Diego, California. No set-aside designation was applied to this award. Travere Therapeutics holds several...
- Travere Therapeutics, Inc. was awarded a $18,542.20 firm fixed price delivery order from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 to supply Thioproin pharmaceutical products. The delivery order was issued under Travere's Pharmaceuticals and Drugs GSA Schedule contract (FSS-61-IB) for products to be delivered to the VA medical facility located in San Diego, California by June 2024. No set-aside designation was applied to this...